Pliant Therapeutics Inc (9PT.F)
| Previous close | 12.50 |
| Open | 12.30 |
| Bid | 12.80 x N/A |
| Ask | 13.20 x N/A |
| Day's range | 12.30 - 12.30 |
| 52-week range | 10.80 - 25.00 |
| Volume | |
| Avg. volume | 12 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)
Pliant Therapeutics ( NASDAQ:PLRX ) First Quarter 2024 Results Key Financial Results Net loss: US$47.0m (loss widened...
GlobeNewswirePliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, at the upcoming European Association for the Study of the Liver (EASL) International Liver Congress™ taking place in Milan, Italy from June 5-8, 2024. Title: Oral alpha-v/beta-6 and alpha
- GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
BEACON-IPF pivotal, adaptive Phase 2b/3 trial design implementation significantly accelerates bexotegrast development in IPF Data from completed 12 week Phase 2a imaging trial measuring bexotegrast’s effect on total lung collagen and FVC in IPF patients expected in the coming weeksRegulatory clearance for muscular dystrophy program PLN-101325 received, allowing conduct of a first-in-human Phase 1 clinical study SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, In
